- Home
- Companies
- SynVivo, Inc.
- Services
- Screening, Assay and New Model ...
Screening, Assay and New Model Development Services
The SynVivo platform has been validated for accurate prediction of in vivo responses. Use this unique in vitro platform for realistic assessment of drug delivery, analysis of cell-cell, cell-drug, and their underlying mechanisms. Recreate cellular and tissue architecture in a Organ-on-Chip format compatible with standard analytical instrumentation. With simultaneous visualization and real-time monitoring of cellular and tissue architecture of desired organs, the SynVivo platform enables identification of toxicity responses to reduce expensive and time-consuming preclinical or clinical trials.
Our assays provide a unique perspective of the realism of an in vivo microenvironment in an in vitro environment for modeling drug delivery, drug discovery, and ADME/Toxicity. Screening Services include target validation, compound screening, biomarker analysis, ADME/Tox, and mechanism of action studies.
Services are offered using our validated 3D tissue models and we also provide custom assay development specifically tailored to meet your goals. Assay Development services can be performed to develop new 3D Tissue and Organ on-Chip models, end-points, or custom chip designs. Our team of engineers and scientists will work closely with your team for the adaptation of the SynVivo platform to develop the right solution for your application.
Monitor Cell-Cell Interactions Between Vascular and Brain Cells
Models available:
- Monoculture with brain endothelial cells
- Co-Culture with brain endothelial cells and astrocytes
- Tri-Culture with brain endothelial cells, astrocytes and pericytes
Assays available:
- Real-time drug permeability across the BBB.
- Neurotoxicity on the cells of the BBB.
- Evaluate drugs that have a protective effect on the BBB
- Investigate the effects of tumor cells on the BBB
- Evaluate inflammatory effects on the BBB
- Biomarker Analysis
- Visualize and quantify the migration of immune cells
- Genomic, proteomic, and metabolic analysis of normal and dysfunctional BBB.
Models Available
- Monoculture using tumor cell lines
- Co-Culture with endothelial cells
- Tri-Culture with stromal and endothelial cells
- Tri-Culture with stromal, endothelial and immune cells
Assays available:
- Efficacy and toxicity screening
- Cell proliferation, morphology, viability
- Tumor-induced vascular leakage
- Tumor Intravasation and extravasation
- Tumor Immune Cell interactions
- Drug delivery, uptake, and efficacy
- Biomarker analysis
- On-chip or off-chip analysis
Models Available:
- Monoculture using primary endothelial cells/cell line
- Co-Culture with stromal/tissue cells
Assays available:
- Immune cells (primary, cell lines) rolling, adhesion and migration across the endothelium
- Inflammation-induced vascular permeability
- Drug-induced vascular injury
- Inflammation-induced biomarker analysis
- Therapeutic screening
- Screening for cell surface biomarkers
- Target identification
- Screening for activators/inhibitors of inflammation
Models available:
- Monoculture using primary epithelial cells
- Co-Culture with endothelial cells
- Tri-culture with fibroblasts
Assays available:
- Toxicity assays
- Biomarker analysis
- Therapeutic screening
Models Available:
- Monoculture using endothelial cells
- Co-Culture with stromal/tissue cells
Assays available:
- Drug-induced vascular leakage
- Vascular inflammation
- Biomarker analysis
- Efficacy and toxicity screening
- Dose-response
- Cell viability
- Mechanism of action studies